Inhibition of miRNA-135a-5p ameliorates TGF-β1-induced human renal fibrosis by targeting SIRT1 in diabetic nephropathy

JUAN ZHANG*, LIAN ZHANG*, DONGQING ZHA and XIAOYAN WU

Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China

Received August 5, 2019; Accepted January 13, 2020

DOI: 10.3892/ijmm.2020.4647

Abstract. miRNA-135a-5p upregulation has been identified in renal fibrosis in diabetic nephropathy (DN) with an incompletely known mechanism. Previous data showed that Sirtuin 1 (SIRT1) serves as a novel therapeutic target for DN and interact with the transforming growth factor-β/mothers against decapentaplegic homolog (TGF-β/Smad) signaling pathway. The aim of this study was to investigate the regulatory relationship between miR-135a-5p and SIRT1. The expression of miR-135a-5p and SIRT1 was detected using reverse transcription-quantitative PCR and western blotting. The renal fibrosis and Smad3 signaling pathway were assessed by western blotting, by analyzing protein expression of collagen1A1, α-smooth muscle actin (α-SMA), fibronectin (FN), epithelial-cadherin, Smad3 and phosphorylated Smad3 (p-Smad3). The target binding between miR-135a-5p and SIRT1 was predicted on TargetScan Human software, and confirmed by dual-luciferase reporter assay and RNA immunoprecipitation. The results demonstrated miR-135a-5p is upregulated and SIRT1 was downregulated in the serum and renal tissue of DN patients, and TGFβ1-induced DN cell models, which could be attenuated by miR-135a-5p knockdown via SIRT1. In conclusion, knockdown of miR-135a-5p inhibits TGFβ1-induced renal fibrosis by targeting SIRT1 and inactivating Smad3 signaling, providing a novel insight into miR-135a-5p as a potential therapeutic approach for DN.

Introduction

Diabetic nephropathy (DN) is a hard microvascular complication of diabetes (1). Histologically, mesangial cell proliferation and podocyte damage are the major pathological features in the early stage of DN (2). DN is structurally characterized by the thickening of glomerular and tubular basement membranes, which have been attributed to extracellular matrix (ECM) synthesis (3-5). Deposition of ECM proteins such as collagens and fibronectin in the tubulointerstitium and glomerular mesangium contribute to tubulointerstitial fibrosis and glomerulosclerosis, eventually resulting in renal fibrosis (6,7). Pathologically, the progression of renal fibrosis is one of the hallmarks of DN and further predicts the deterioration of renal function (8,9). Considering that tubulointerstitial fibrosis is the key underlying pathology, understanding the regulatory mechanism underlying fibrogenesis in the interstitium is key to developing therapeutic targets for DN (10). However, to date, the option to target renal fibrosis is still not available in the clinic. Thus, more molecular pathways should be identified for new therapeutic strategies for DN.

Transforming growth factor-β (TGFβ) is a vital cytokine that promotes sclerosis and has been well documented in fibrosis development in DN (11). Highly expressed TGFβ occurs universally in chronic kidney diseases in both animal models and humans. For example, animal models of spontaneous diabetes have demonstrated increased TGFβ mRNA expression at the onset of hyperglycemia (12,13); in addition, TGFβ receptors have been described to be upregulated in renal disease models including DN. A previous study revealed that TGFβ was increased in several types of cells in the diabetic kidney, including mesangial cells, thus contributing to fibrotic events and cell survival (10). Therefore, TGFβ has been evaluated as a major target for DN treatment. In addition, evidence indicates a primary role for TGFβ and its downstream signaling cascades in the progression of renal diseases (14). TGFβ regulates numerous cell behaviors including cell proliferation, differentiation, adhesion and apoptosis (15,16). In addition, several intracellular signaling cascades have been identified

*Contributed equally

Abbreviations: DN, diabetic nephropathy; SIRT1, sirtuin 1; HMC, human mesangial cells; α-SMA, α-smooth muscle actin; FN, fibronectin; ECM, extracellular matrix; TGFβ, transforming growth factor-β; Smad, mothers against decapentaplegic homolog; MAPK, mitogen activated protein kinase

Key words: miR-135a-5p, sirtuin 1, mothers against decapentaplegic homolog 3, renal fibrosis, diabetic nephropathy
for TGFβ-induced renal fibrosis, such as the mothers against decapentaplegic homologs (Smads), mitogen activated protein kinase (MAPK) and Jagged/Notch signaling pathway (10). Thus, it is important to further understand the molecular mechanisms of TGFβ-induced fibrotic events, which may lead to more effective approaches for DN treatment.

MicroRNAs (miRNAs/miRs) are highly conserved small non-coding RNAs (~22 nucleotides) with no protein coding capacity. Generally, miRNAs act as a mediator of functional gene expression by interacting with the 3' untranslated region (3'UTR) of the target gene. It has been proposed that miRNAs modulate the effects of TGFβ1 in renal fibrosis, such as miRNA (miR)-433 (17). Cumulative evidence has demonstrated the close association between dysregulation of miRNAs and the progression of diabetes and diabetic complications, including DN (18,19). A number of miRNAs have been identified as early biomarkers in various chronic kidney diseases due to their consistency and reproducibility in human peripheral blood (20). In addition, integrated serum miRNAs expression profiling may be used in DN for identification of novel miRNAs (21). Among them, miR-135a-5p was significantly upregulated in the serum and renal tissues from patients with DN compared with healthy controls (21). However, the role and mechanism of miR-135a-5p in DN hasn’t been fully illuminated.

Sir2uin 1 (SIRT1) belongs to a highly conserved family of NAD+−dependent deacetylase and serves as a therapeutic target for DN (22). The present study aimed to investigate the expression of miR-135a-5p in peripheral blood of patients with DN, as well as the role and mechanism of miR-135a-5p in TGFβ1-induced cell model of renal fibrosis.

Materials and methods

Clinical specimens. Patients were diagnosed with DN confirmed by renal biopsy, with nodular sclerosis (Kinnelstiel-Wilson lesion) in the glomerulus between January 2015 and December 2017. Peripheral venous blood samples were collected from 30 patients with DN (age, 43-73 years; male, 46.7%) and 30 patients with diabetes without DN (age, 38-68 years; male, 50.0%) after informed consent was provided by each individual. The clinical characteristics of the participants are presented in Table I. The blood samples were snap-frozen in liquid nitrogen (-79°C). All protocols involving human subjects were approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University. The renal tissue sections were obtained from 10 of 30 renal biopsy specimens, and the control tissues were adjacent normal renal tissue sections from patients with renal carcinoma with normal kidney function (data not shown).

Cells and cell culture. Human proximal tubule cell lines (HK-2, cat. no. CRL-2190) were purchased from the American Type Culture Collection, and a human renal mesangial cell line (HMC, cat. no. 4200) was obtained from ScienCell Research Laboratories, Inc. HK-2 and HMCs were cultured and passaged in growth culture medium containing 90% Dulbecco's modified Eagle medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.), 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in a humidified environment containing 5% CO2 for indicated times.

TGFβ1 treatment and high glucose treatments. HK-2 and HMCs at 60% confluency were seeded into 6-well plates (Corning, Inc.) overnight. For TGFβ1 treatment, the cells were made quiescent by incubation with serum-free medium for 16 h when grown to 80-90% confluence. A recombinant human TGFβ1 (cat. no. P01137; R&D Systems, Inc.) at a concentration of 10 ng/ml was added to the cell growth culture for 24 h to detect changes in the expression of miR-135a-5p and SIRT1, fibrosis response and TGFβ1/Smad3 signaling. For high glucose treatment, different concentrations of D-glucose (5-30 mmol/l) were added into DMEM, and HMC and HK-2 cells were incubated for 48 h before detection of miR-135a-5p expression.

Cell transfection. HK-2 and HMCs at 60% confluency were seeded into 6-well plates (Corning, Inc.) and incubated overnight. miR-135a-5p mimic (5'-UAUGGCUUUUAUUCUAAUGUGA-3'), miR-135a-5p inhibitor (anti-miR-135a-5p; 5'-UCACAUGGAUAAUAGCCAU-3'), specific small interfering (si)RNA against SIRT1 (siSIRT1; sense, 5'-GAAGUGAUCUCUCCATT-3' and antisense, 5'-UGAGGA GGUACAUCUAUCCT-3') and the corresponding negative controls miR-NC mimic (5'-GUCAGAGAUUUCCAG-3'), anti-NC (5'-TCACAAACTCTTCTAGAAAGATGTA-3') and siNC (sense, 5'-TTTCCTCGAAGCTTGCACGT-3' and antisense, 5'-ACGGUGACGCGUGGAGA-3') were acquired from Shanghai GenePharma Co., Ltd. The overexpression of SIRT1 was performed using a pcDNA3.1 plasmid (Invitrogen; Thermo Fisher Scientific, Inc.). All transfections of oligonucleotides (30 nM) or vectors (2 µg) were performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), and the transfected cells were collected for further analysis after transfection for 36 h.

Reverse transcription-quantitative PCR (RT-qPCR). For examination of the expression of SIRT1 mRNA and miR-135a-5p, total RNA was extracted from blood and treated cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The first-strand cDNA was synthesized at 42°C for 15 min using Fastking RT kit (Tiangen Biotech Co., Ltd.) and miRNA First-Strand cDNA Synthesis kit (Tiangen Biotech Co., Ltd.). qPCR was performed with SuperReal PreMix Plus (SYBR Green; Tiangen Biotech Co., Ltd.) on the ABI PRISM 7500 Fast Real-time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were 40 cycles of 95°C for 15 sec, 60°C for 60 sec and 95°C for 15 sec. Relative gene expression was normalized to GAPDH (for miRNAs) and U6 small nuclear RNA (U6; for miR-135a-5p). The reactions were performed in at least three independent runs using the following primers: SIRT1 isoform 2 forward, 5'-TGTGTCTATA GGTGTTGTTGTTGA-3' and reverse, 5'-AGCAATACTTT TTTGTTTTGTT-3'; GAPDH forward, 5'-CTGGGCTTAC ACTGAGCAC-3' and reverse, 5'-AAGTGCTGTTGTTAG GCAATG-3'; miR-135a-5p forward, 5'-TTTGGTCTTGGT CCCGGTCC-3' and reverse, 5'-TCACAGCTCCCCAGCT AAC-3'; U6 forward, 5'-CTCGCTTCCGGCCAGCACA-3' and
reverse, 5'-AACGCTTCAGAATTTGCCGT-3'. Expression levels were normalized to the respective internal controls and calculated using the $2^{-ΔΔCq}$ method (23).

**Western blotting.** To examine the expression of collagen I, α-smooth muscle actin (α-SMA), fibronectin (FN) and epithelial (E)-cadherin, total protein was extracted from blood and treated cells using RIPA lysis buffer (Beyotime Institute of Biotechnology) supplemented with the protease inhibitor phenylmethanesulfonyl fluoride (MedChemExpress). A total of 20 µg of protein determined by Bradford protein assay (Bio-Rad Laboratories, Inc.) was loaded for the standard procedures of western blotting. The proteins were transferred to PVDF membranes and incubated in a blocking buffer (3% BSA; R&D Systems, Inc.) for 1 h at 25°C and with primary antibodies overnight at 4°C. The primary antibodies against SIRT1 (cat. no. 8469; 1:1,000), collagen1A1 (cat. no. 84336; 1:1,000), α-SMA (cat. no. 14968; 1:1,000), E-cadherin (cat. no. 14472; 1:1,000), Smad3 (cat. no. 9513; 1:1,000), phosphorylated (p)-Smad3 (cat. no. 9520; 1:1,000) and GAPDH (cat. no. 97166; 1:1,000) were purchased from Cell Signaling Technology, Inc. The antibody against FN (cat. no. 8422; 1:200) was provided by Santa Cruz Biotechnology, Inc. After that, the membranes were washed with Tris-buffered saline containing 0.1% Tween-20, and then incubated with horseradish peroxidase-conjugated secondary mouse (cat. no. 7076; 1:2,500) or rabbit (cat. no. 7074; 1:2,500) antibody from Cell Signaling Technology, Inc. supplemented with the protease inhibitor phenylmethanesulfonyl fluoride (MedChemExpress). A total of 20 µg of protein determined by Bradford protein assay (Bio-Rad Laboratories, Inc.) was loaded for the standard procedures of western blotting. The proteins were transferred to PVDF membranes and incubated in a blocking buffer (3% BSA; R&D Systems, Inc.) for 1 h at 25°C and with primary antibodies overnight at 4°C. The primary antibodies against SIRT1 (cat. no. 8469; 1:1,000), collagen1A1 (cat. no. 84336; 1:1,000), α-SMA (cat. no. 14968; 1:1,000), E-cadherin (cat. no. 14472; 1:1,000), Smad3 (cat. no. 9513; 1:1,000), phosphorylated (p)-Smad3 (cat. no. 9520; 1:1,000) and GAPDH (cat. no. 97166; 1:1,000) were purchased from Cell Signaling Technology, Inc. The antibody against FN (cat. no. 8422; 1:200) was provided by Santa Cruz Biotechnology, Inc. After that, the membranes were washed with Tris-buffered saline containing 0.1% Tween-20, and then incubated with horseradish peroxidase-conjugated secondary mouse (cat. no. 7076; 1:2,500) or rabbit (cat. no. 7074; 1:2,500) antibody from Cell Signaling Technology, Inc. at 25°C for 1.5 h. Protein bands were finally detected by using an enhanced chemiluminescent substrate (Pierce; Thermo Fisher Scientific, Inc.) and the gray intensity determined on Image-Pro Plus 6.0 software (Media Cybernetics, Inc.).

**Luciferase reporter assay and RNA immunoprecipitation (RIP).** According to bioinformatics algorithms, human SIRT1 3' untranslated region (UTR) contained a potential target site of hsa-miR-135a-5p. Then, the wild type of SIRT1 3' UTR fragment (SIRT1-wt) containing AAAAAAGCAU was cloned by PCR methods into pGL4 vector (Promega Corporation), as well as the mutated SIRT1 3' UTR sequence (SIRT1-mut) containing UUUUUCGGUA. HK-2 and HMCs were transfected according to the following groups: SIRT1-wt + miR-NC mimic, SIRT1-wt + miR-135a-5p mimic, SIRT1-wt + miR-NC mimic, SIRT1-wt + miR-135a-5p mimic. After incubation for 24 h, cells were collected to measure Firefly and Renilla luciferase activities using the Dual-Luciferase Reporter assay system (Promega Corporation).

**Statistical analysis.** Data are presented as the mean ± standard error of the mean from three independent experiments and were analyzed using SPSS 19.0 software (SPSS, Inc.). The P-values were evaluated using one-way analysis of variance followed by Tukey's post hoc test. Spearman's rank correlation analysis was performed to confirm the correlation between miR-135a-5p and SIRT1 in DN patients. P<0.05 was considered to indicate a statistically significant difference.

**Results**

miR-135a-5p is upregulated and SIRT1 is downregulated in patients with DN. Previous studies suggested the enhancement of miR-135a-5p expression in renal fibrosis and the important role of SIRT1 in mesangial cells and renal fibrosis (12,18). Consistently, the present study observed a significantly increased expression of miR-135a-5p (Fig. 1A) and a lower expression of SIRT1 (Fig. 1B and C) in the serum of patients with DN (n=30, Table I) as measured by RT-qPCR and western blotting. Moreover, the expression of miR-135a-5p and SIRT1 in the renal tissues was also detected. As presented in Fig. 1A and B, miR-135a-5p was upregulated, whereas SIRT1 was downregulated in the 10/30 renal biopsy specimens compared with normal renal tissues. In addition, there was a negative correlation between miR-135a-5p and SIRT1 expression in renal tissues of DN patients, according to Spearman's rank correlation analysis (Fig. S1C). These data suggested that miR-135a-5p and SIRT1 were involved in renal fibrosis.

miR-135a-5p expression is increased during TGFβ1-induced renal fibrosis in vitro. To examine the relevance of miR-135a-5p in renal fibrosis in DN, a cell model of renal fibrosis in HMC and HK-2 cells was constructed. First, miR-135a-5p

Table I. Clinical characteristics of patients with DN or healthy controls (Control).

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>DN (n=30)</th>
<th>Control (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean years</td>
<td>60.23</td>
<td>62.45</td>
</tr>
<tr>
<td>Sex, male/female</td>
<td>16/14</td>
<td>15/15</td>
</tr>
<tr>
<td>UAER, µg/min</td>
<td>248.75</td>
<td>14.35</td>
</tr>
<tr>
<td>Scr, µmol/l</td>
<td>120.35</td>
<td>63.27</td>
</tr>
<tr>
<td>BUN, mmol/l</td>
<td>12.87</td>
<td>5.35</td>
</tr>
</tbody>
</table>

UAER, urine albumin excretion rate; BUN, blood urea nitrogen; Scr, serum creatinine; DN, diabetic nephropathy.
expression was monitored in various glucose concentration stimulation in HMC and HK-2 cells. As a result, 15-30 mmol/l of D-glucose induced an increase in miR-135a-5p expression at 48 h (Fig. S2). Subsequently, HMC and HK-2 cells were exposed to 10 ng/ml TGFβ1 for 24 h for renal fibrosis analysis. As presented in Fig. 2A, miR-135a-5p was highly expressed in TGFβ1-induced HMC and HK-2 cells. The levels of collagen 1A1, α-SMA and FN were significantly promoted, whereas E-cadherin was inhibited under TGFβ1 stimulation (Fig. 2B). These data suggested that TGFβ1 treatment induced renal fibrosis in HMC and HK-2 cells, accompanied with upregulation of miR-135a-5p.
Knockdown of miR-135a-5p inhibits TGFβ1-induced renal fibrosis in HMC and HK-2 cells. Considering the upregulation of miR-135a-5p during renal fibrosis, miR-135a-5p was knocked down in HMC and HK-2 cells by transient transfection of anti-miR-135a-5p. During TGFβ1 exposure, anti-miR-135a-5p-transfected cells exhibited lower expression levels of miR-135a-5p compared with that of anti-NC-transfected cells (Fig. 3A). In addition, the levels of collagen 1A1, α-SMA and FN were decreased under TGFβ1 stimulation when miR-135a-5p was knocked down, whereas that of E-cadherin increased (Fig. 3B).

Figure 3. Effects of the miR-135a-5p inhibitor on TGFβ1-induced HMC and HK-2 cells. miR-135a-5p expression in HMC and HK-2 cells was silenced by transient transfection of anti-miR-135a-5p. (A) Levels of miR-135a-5p were detected by reverse transcription-quantitative PCR. (B) Levels of collagen 1A1, α-SMA, FN and E-cadherin were measured by western blotting. *P<0.05 vs. anti-NC cells. FN, fibronectin; SMA, smooth muscle actin; TGF, transforming growth factor; HMC, human mesangial cells; miR, microRNA; E, epithelial; NC, negative control.
E-cadherin was elevated compared with anti-NC-transfected cells (Fig. 3B). These results demonstrated that miR-135a-5p knockdown may alleviate TGF β1-induced renal fibrosis in HMC and HK-2 cells.

**SIRT1 is downregulated, and overexpression of SIRT1 exerts a suppressive role in TGFβ1-induced renal fibrosis in vitro.** To examine the effects of SIRT1 in renal fibrosis in DN, the present study determined its expression in a cell model of renal fibrosis in HMC and HK-2 cells. As presented in Fig. 4A, SIRT1 was expressed at a low level in TGF β1-induced HMC and HK-2 cells. Thus, SIRT1 was overexpressed in HMC and HK-2 cells using ectopic expression of a recombinant vector pcDNA-SIRT1 (SIRT1). (C) Expression of collagen I, α-SMA, FN and E-cadherin was measured by western blotting in SIRT1-overexpressed HMC and HK-2 cells. *P<0.05 vs. control cells (vector). FN, fibronectin; SMA, smooth muscle actin; TGF, transforming growth factor; HMC, human mesangial cells; miR, microRNA; E, epithelial; NC, negative control; SIRT1, sirtuin 1.

miR-135a-5p regulates SIRT1 expression via target binding. The regulatory relationship between miR-135a-5p and SIRT1 was further investigated. Algorithms analysis by TargetScan Human database (http://www.targetscan.org/vert_72/) identified the targets of miR-135a-5p, and the 3’UTR of human SIRT1 exhibited a highly conserved binding site for miR-135a-5p (Fig. 5A). To verify this, a luciferase reporter assay was performed to further identify the level of SIRT1 mRNA in HMC and HK-2 cells co-transfected with anti-miR-135a-5p or NC. (D) Western blotting was used to analyze the SIRT1 protein levels in HMC and HK-2 cells transfected with anti-miR-135a-5p, miR-135a-5p and the corresponding controls. Data were plotted as the mean ± standard error of the mean and performed in triplicate. *P<0.05 vs. control cells (NC or anti-NC). FN, fibronectin; SMA, smooth muscle actin; TGF, transforming growth factor; HMC, human mesangial cells; miR, microRNA; E, epithelial; NC, negative control; UTR, untranslated region; mut, mutant; wt, wild-type; miR-135a-5p, miR-135a-5p mimic; anti-miR-135a-5p, miR-135a-5p inhibitor.
Figure 6. Influence of SIRT1 silencing on TGFβ1-induced HMC and HK-2 cells. HMC and HK-2 cells were transfected with siRNA against human SIRT1 (siSIRT1), and effect of SIRT1 downregulation in miR-135a-5p-knocked down cell was evaluated using western blotting. (A) Levels of SIRT1 were detected. (B) Expression of collagen1A1, α-SMA, FN and E-cadherin was measured. The quantification was performed on Image J. Data were plotted as mean ± standard error of mean and performed in triplicate. *P<0.05 vs. control cells (anti-NC or anti-miR-135a-5p+scramble). FN, fibronectin; SMA, smooth muscle actin; TGF, transforming growth factor; HMC, human mesangial cells; miR, microRNA; E, epithelial; NC, negative control; si, small interfering.
performed. The luciferase reporter vectors integrating wt or mut SIRT1 3'UTR fragment were constructed, and HMC and HK-2 cells were co-transfected with SIRT1-wt/mut and either miR-135a-5p or miR-NC mimic. First, RT-qPCR analysis was used to confirm the high miR-135a-5p expression level in the mimic-transfected HMC and HK-2 cells (Fig. S3A). The luciferase activity was significantly reduced in cells transfected with the miR-135a-5p mimic and SIRT1-wt; however, no differences were observed in the SIRT1-mut groups (Fig. 5B). RIP assay further identified the target binding of miR-135a-5p and SIRT1 (Fig. 5C). A western blot assay demonstrated that SIRT1 expression was inhibited by the miR-135a-5p mimic but promoted by anti-miR-135a-5p in HMC and HK-2 cells compared with the corresponding NCs (Fig. 5D). These data supported the hypothesis that SIRT1 was a direct target of miR-135a-5p.

SIRT1 mediates the role of miR-135a-5p knockdown in TGFβ1-induced renal fibrosis in vitro. Rescue experiments were performed to clarify the effects of SIRT1 dysregulation on the role of miR-135a-5p in HK-2 and HMC cells. As presented in Fig. 6A, HMC and HK-2 cells were divided into four transfection groups: Anti-NC, anti-miR-135a-5p, anti-miR-135a-5p + scramble and anti-miR-135a-5p + siSIRT1. The upregulation of SIRT1 induced by anti-miR-135a-5p was impaired by siSIRT1 (Fig. 6A), and western blotting confirmed that siSIRT1 transfection caused a significant decrease of the SIRT1 level in HMC and HK-2 cells compared with the scramble siRNA-transfected cells (Fig. S3B). When miR-135a-5p was inhibited, collagen 1A1, α-SMA and FN synthesis was reduced compared with the NC group, which was blocked by silencing of SIRT1 (Fig. 6B). Knockdown of SIRT1 abolished the effects of anti-miR-135a-5p on E-cadherin expression as indicated in Fig. 6B. These results demonstrated that miR-135a-5p knockdown inhibited TGFβ1-induced renal fibrosis by upregulating SIRT1.

miR-135a-5p knockdown inactivates the TGFβ1/Smad3 signaling pathway through upregulating SIRT1. To explore the signaling pathway underlying the activity of miR-135a-5p during TGFβ1-induced renal fibrosis, Smad3 activation was measured. The upregulation of p-Smad normalized to total Smad3 was observed in HMC and HK-2 cells under TGFβ1 stimulation compared with that in untreated cells (Fig. 7A). The relative level of p-Smad3 was significantly reduced in the anti-miR-135a-5p group compared with that in the anti-NC group; in addition, the inactivation of Smad3 induced by miR-135a-5p knockdown was reversed by silencing SIRT1 in HMC and HK-2 cells (Fig. 7B). These results indicated that the inhibition of the TGFβ1/Smad3 signaling pathway was involved in the role of miR-135a-5p/SIRT1 in renal fibrosis in vitro.

Discussion

In China, diabetes has become a major public health problem (24), and ~10% of patients with diabetes suffer from DN (25). Progressive renal fibrosis is one of the hallmark pathological characteristics of DN (8). For example, the fibrosis-related genes collagen I, FN, E-cadherin and α-SMA...
were upregulated in a mouse model of DN (26). Bai et al (27) observed that the levels of Snail, Vimentin, collagen IV and α-SMA were upregulated, and E-cadherin was downregulated in 86 renal biopsies of DN. Putta et al (28) reported that silencing of miR-192 caused downregulation of key profibrotic genes such as collagen 1A2, collagen 4A1 and FN in the glomeruli and cortex of diabetic mice. In addition, it was also suggested that the epithelial-mesenchymal transition (EMT) served as one potential mechanism underlying renal fibrosis in DN (29,30). In the current study, TGFβ1 treatment induced renal fibrosis in HMC and HK-2 cells as demonstrated by the increased synthesis of collagen 1A1, α-SMA and FN, as well as by decreased expression of E-cadherin.

Numerous miRNAs have been reported to be involved in renal fibrosis in DN. For example, Zhao et al (31) demonstrated that miR-23b was expressed at a lower level in the serum of patients with diabetes mellitus and concluded that miR-23b had a protective effect against renal fibrosis in DN. Expression of miR-192 was upregulated by TGF-β1 in cultured glomerular mesangial cells and diabetic glomeruli of mice (28). The specific reduction of renal miR-192 decreased renal fibrosis and improve proteinuria. These results supported the possibility of an anti-miRNA-based translational approach to the treatment of DN. The results of the present study demonstrated that inhibition of miR-135a-5p upregulation of E-cadherin levels, but reduced collagen 1A1, α-SMA, and FN expression in TGFβ1-induced HMC and HK-2 cells. The present results also revealed that SIRT1 was a target gene of miR-135a-5p, and silencing of SIRT1 abolished the effects of miR-135a-5p on renal fibrosis. In addition, Smad3 activation was altered by miR-135a-5p/SIRT1 in HMC and HK-2 cells.

As an oncogene, miR-135a-5p promotes cell proliferation and metastasis in hepatocellular carcinoma (32,33) and breast cancer (34). However, miR-135a-5p served as an anti-oncogene and targeted HOXA10 to suppress the proliferation of head and neck squamous cell carcinoma (35). Thus, miR-135a-5p may serve a dual role in cancers. In diabetes, expression of this miRNA is considered to be upregulated. For instance, Agarwal et al (36) observed elevated miR-135a-5p levels in human diabetic skeletal muscle. Upregulation of miR-135a-5p was also identified in the serum miRNA expression profile and renal tissues from patients with DN (21). In addition, the biological role and mechanism of miR-135a-5p was preliminarily explored, and the results demonstrated that miR-135a-5p upregulation promoted mesangial cell proliferation by decreasing G1/S arrest and increasing synthesis of ECM proteins such as FN, Vimentin, and collagen I by directly regulating short transient receptor potential channel 1 in a HMC line (21); by contrast, silencing of miR-135a-5p alleviated hyperglycemia and improved glucose tolerance in vivo (36). Thus, miR-135a-5p may be associated with fibrosis and diabetes. The present study focused on the expression of miR-135a-5p in patients with DN, as well as its biological role in TGFβ1-induced renal fibrosis cell models in HMC and HK-2 cells. The results demonstrated that the expression levels of miR-135a-5p were increased in the sera and renal tissues of patients with DN as well as in HMC and HK-2 cells under various glucose concentrations or TGFβ1 stimulation. Functionally, anti-miR-135a-5p attenuated the expression of collagen 1A1, α-SMA and FN, and elevated the levels of E-cadherin under TGFβ1 stimulation in vitro, which was in agreement with the previous findings by He et al (21). In addition, SIRT1 has been demonstrated to mediate the inhibitory activity of miR-135a-5p in the synthesis of fibrosis-related genes. Of note, Wu et al (37) recently investigated the role and possible regulatory mechanism of miR-135a-5p in cardiac fibrosis and reported that cardiac fibroblasts from neonatal rats induced by isoproterenol was inhibited by miR-135a-5p targeting the transient receptor potential metalastatin 7. Simultaneously, miR-135a-5p was decreased in ISO-induced cardiac fibrosis in vitro and in vivo (37). These results suggested the complex and vital role of miR-135a-5p in the biological functions of diseases, including cancer and diabetes complications.

SIRT1 has been demonstrated to serve a crucial role in miscellaneous physiological processes through the deacetylation of a number of nuclear proteins such as p53 and NF-kB (22,38,39). Previous studies have demonstrated that SIRT1 reduces apoptosis in TGFβ1-treated mesangial cells via acceleration of Smad7 degradation and the TGFβ signaling pathway (40). In addition, SIRT1 regulates fibroblast activation and tissue fibrosis by canonical TGFβ signaling (10). Inhibition of SIRT1 promotes TGFβ1-induced EMT and renal fibrosis in HK-2 cells (26). Accumulating evidence has indicated SIRT1 is affected by miRNAs during fibrogenesis, including that in the kidney. For example, inhibition of miR-133b and miR-199b attenuated TGFβ1-induced EMT and renal fibrosis by targeting SIRT1 (26). miR-34a targeting SIRT1 aggravated high glucose-stimulated tubulointerstitial fibrosis in HK cells (41,42). In the present study, the results demonstrated that SIRT1, which is a vital regulator in the evolution of renal fibrosis in DN (22), was directly suppressed by miR-135a-5p. Furthermore, the current study proposed that the miR-135a-5p/SIRT1 axis may provide a new approach for DN treatment.

Previously, SIRT1 activation had been suggested as a therapeutic strategy in progressive, fibrotic diseases in the kidney, liver, lung and heart (14,43-45). Mechanically, inhibition of the TGFβ1/Smad3 pathway has been attributed to the protective role of SIRT1 activation in organ fibrosis including renal fibrosis (14). For example, co-immunoprecipitation assays have provided direct evidence of an interaction between acetylated Smad3 and SIRT1 (14,46). In the kidney, knockdown of SIRT1 increases the levels of acetylated Smad3, thus substantially enhancing the transcriptional activity of Smad3 following TGF-β1 treatment (14). Additionally, the allosteric modifier of SIRT1 deacetylase ameliorates the TGFβ1-stimulated collagen production, which is accompanied by a reduction of Smad3 reporter activity (47). The present study indicated that the miR-135a-5p/SIRT1/Smad3 pathway was involved in TGFβ1-induced renal fibrosis.

One limitation of the current study was that it did not verify the suppressive activity of miR-135a-5p in diabetic db/db mice by injection of recombinant lentivirus containing miR-135a-5p inhibitor (21,26,28). Furthermore, immunohistochemistry examination of the kidney was not performed (14). TGFβ regulates biological processes by interacting with Smads, MAPK and Jagged/Notch signaling pathways (10). The results of the present study suggested that the miR-135a-5p/SIRT1 axis regulated Smad3 activation; it would be interesting to verify
whether the other two signaling pathways may be altered by the functions of the miR-135a-5p/SIRT1 axis. Therefore, the identification of molecular pathways underlying DN would be imperative for development of new therapeutic strategies.

In conclusion, the results of the present study demonstrated that miR-135a-5p knockdown attenuated renal fibrosis in DN by targeting SIRT1 and inactivating the TGFβ1/Smad3 pathway. These results supported the hypothesis that miR-135a-5p may be a novel therapeutic target in suppressing renal fibrosis in DN.

Acknowledgements

Not applicable.

Funding

This study was supported by the Health Commission of Hubei Province scientific research project ‘The role and mechanism of interferon regulatory factor 8 in renal tubular injury in diabetic nephropathy’ (project no. WJ2019M210) and The Wuhan Science and Technology Bureau (grant no. 2017060201010179).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

JZ and LZ conceived and designed the experiments. DZ performed the experiments and acquired funding. XW and JZ contributed the reagents/materials/analysis tools and performed data analysis and interpretation. LZ wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All protocols involving human subjects were approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University. Informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


